Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line

International Journal of Cancer

Volumn 110, Issue 5, 2004, Pages 627-632

  Miaoi, Ze Hong ^a   Tong, Lin Jiang ^a   Zhang, Jin Sheng ^a   Han, Jia Xian ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

A549 SAL cell line; Antineoplastic agents; Drug resistance; Salvicine

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; CAMPTOTHECIN DERIVATIVE; CHLORMETHINE; CISPLATIN; CISPLATIN DERIVATIVE; DITERPENOID; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GYRASE INHIBITOR; MELPHALAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P21; QUINONE DERIVATIVE; SALVICINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CELL MIGRATION; CHINESE MEDICINE; CONTROLLED STUDY; DRUG MECHANISM; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MDR 1 GENE; PCNA GENE; PHENOTYPE; PHYTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IN SITU NICK-END LABELING; K562 CELLS; NAPHTHOQUINONES; NEOPLASM INVASIVENESS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2942584848     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20026     Document Type: Article

References (32)

1. Yang BJ, Huang XL, Huang Y, Wang XM, Lin LL, But PH, Zhuang GF. Study on the chemical constituents of salvia prionitis. Acta Bot Sin 1988;30:524-7.
2. Lin LZ, Wang XM, Huang XL, Huang Y, Yang BJ. A new diterpenoid quinone dehydromiltirone. Acta Pharm Sin 1988;23:273-5.
3. Huang XL, Wang XM, Huang Y, Zhang JS, Lin L-Z. Structural elucidation of salpriolactone. Acta Bot Sin 1990;32:490-1.
4. Lin LZ, Wang XM, Huang XL, Huang Y. A new diterpenoid quinone supriparaquinone. Acta Pharm Sin 1990;25:154-6.
5. Zhang JS, Ding J, Tang Q, Li M, Zhao M, Lu LJ, Chen LJ, Yuan ST. Synthesis and antitumor activity of novel diterpenequinone salvicine and the analogs. Bioorg Med Chem Lett 1999;9:2731-6.
6. Qing C, Zhang JS, Ding J. In vitro cytotoxicity of salvicine, a novel diterpenoid quinone. Acta Pharm Sin 1999;20:297-302.
7. Meng LH, He XH, Zhang JS, Ding J. DNA topoisomerase II as primary cellular target for salvicine in Saccharomyces cerevisiae. Acta Pharmacol Sin 2001;21:741-6.
8. Meng LH, Zhang JS, Ding J. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effect by trapping the enzyme-DNA cleavage complex. Biochem Pharmacol 2001;62:733-41.
9. Miao Z-H, Tang T, Zhang Y-X, Zhang J-S, Ding J. Cytotoxicity, apoptosis induction and downregulation of mdr-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant cells. Int J Cancer 2003,106:108-15.
10. Miao Z-H, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003, 63:4527-32.
11. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
12. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 1995;87:1593-602.
13. Xiao D, Tan W, Li M, Ding J. Antiangiogenic potential of 10-hydroxycamptothecin. Life Sci 2001;69:1619-28.
14. Rouzaut A, Lopez-Moratalla N, de Miguel C. Differential gene expression in the activation and maturation of human monocytes. Arch Biochem Biophys 2000;374:153-60.
15. Wedemeyer N, Gohde W, Potter T. Flow cytometric analysis of reverse transcription-PCR products: Quantification of p21WAF1/CIP1 and proliferating cell nuclear antigen mRNA. Clin Chem, 2000;46:1057-64.
16. Dilla T, Velasco JA, Medina DL, Gonzalez-Palacios JF, Santisteban P. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells. Endocrinol 2000;141:420-9.
17. Zou C, Guan Y, Zou C, Wang J, Wang LE, Liebert M, Grossman HB, Wei Q. N-(4-hydroxyphenyl) retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines. Cancer Lett 2002;180:131-7.
18. Wedemeyer N, Gohde W, Potter T. Flow cytometric analysis of reverse transcription-PCR products: Quantification of p21WAF1/CIP1 and proliferating cell nuclear antigen mRNA. Clin Chem 2000;46:1057-64.
19. Schaich M, Illmer T, Seitz G, Mohr B, Schakel U, Beck JF, Ehninger G. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. Haematolica 2001;86:470-7.
20. Wu W, Fan Y, Bonnie LK, Garret W, Li M. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 1998;58:4082-5,
21. Takeuchi A, Kaneko S, Matsushita E, Urabe T, Shimoda A, Kobayashi K. Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines. J Gastroenterol 1999;34:351-8.
22. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998;58:1558-61.
23. Fiebig HH, Burge AM. Relevance of tumor models for anticancer drug development. Basel: Karger Press. 1999.
24. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
25. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002;2:48-58.
26. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990 42:155-99.
27. Bates SE. Drug resistance: still on the learning curve. Clin Cancer Res 1999;5:3346-8.
28. Lane DP, Hupp TR. Drug discovery and p53. Drug Discov Today 2003;8:347-55.
29. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH.c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-5.
30. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
31. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 1999;43:S3-10.
32. Yang JM, Yang GY, Medina DJ, Vassil AD, Liao J, Hait WN. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. Biochem Biophys Res Commun 1999;266:167-73.